Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 18F-FDG (Fluorodeoxyglucose) PET Clear all
Completed Not applicable Interventional

Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer

NCT00081094
View directory record Official record
Conditions
Liver Cancer
Interventions
18F-Fluorodeoxyglucose-PET (FDG-PET), 11Carbon-Acetate-PET
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Not applicable Interventional

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

NCT05174026
View directory record Official record
Conditions
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

NCT00559377
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography, tissue oxygen measurement
Other · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 5, 2026, 5:47 PM EDT
Recruiting Phase 2Phase 3 Interventional

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537
View directory record Official record
Conditions
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions
Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
106
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

NCT00238368
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 5, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water

NCT01246869
View directory record Official record
Conditions
Brain Cancer
Interventions
[18F]fluoro-2-deoxy-D-glucose (FDG), 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole, [15O]water, Magnetic Resonance Imaging
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 5, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00809341
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Ifosfamide, Carboplatin, Etoposide, High-dose cyclophosphamide, PET scan
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 5, 2026, 5:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Brown Adipose Tissue by Magnetic Resonance Imaging

NCT02237872
View directory record Official record
Conditions
Obesity, Brown Adipose Tissue
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 5, 2026, 5:47 PM EDT
Enrolling by invitation Not applicable Interventional

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

NCT03032601
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
N-acetyl Cysteine
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 5, 2026, 5:47 PM EDT
Not listed No phase listed Observational

FDG an Myocardial Infarction: The PIAF Trial

NCT05138718
View directory record Official record
Conditions
History of Myocardial Infarction
Interventions
18F-FDG PET/CT
Diagnostic Test
Lead sponsor
International Atomic Energy Agency
Government
Eligibility
18 Years to 80 Years
Enrollment
2,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Total-Body Parametric 18F-FDG PET of COVID-19

NCT04841707
View directory record Official record
Conditions
Covid19
Interventions
uEXPLORER/mCT
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Comparison of 18F FDG PET/CT TO PET MRI

NCT01986985
View directory record Official record
Conditions
Any Condition With a Clinical Indication for PET/CT Exam
Interventions
PET/MRI system
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 5, 2026, 5:47 PM EDT
Recruiting Phase 1 Interventional

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT04780568
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Intermittent, Claudication, PAD, SFA - Superficial Femoral Artery Stenosis, Iliac Artery Disease, Vascular Calcification
Interventions
18F-FDG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 5, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Terminated Not applicable Interventional Results available

Use of PET Imaging to Distinguish Malignant From Benign IPMN

NCT01104116
View directory record Official record
Conditions
Neoplasm, Pancreatic Cancer
Interventions
[18F]-FDG PET/CT imaging
Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 5, 2026, 5:47 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04478318
View directory record Official record
Conditions
Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions
uEXPLORER/mCT, mCT/uEXPLORER
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

T Cell Effector and Regulatory Mechanisms in Asthma

NCT01612936
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Biological · Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer

NCT01655745
View directory record Official record
Conditions
Bladder Cancer
Interventions
FDG PET/MR
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 5, 2026, 5:47 PM EDT
Completed No phase listed Observational

Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis

NCT05062395
View directory record Official record
Conditions
Myocarditis Acute
Interventions
Computed Tomography, Fludeoxyglucose F-18, Low Carbohydrate High Fat Diet, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 5, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

Comparison of Whole Body DWI to FDG PET

NCT06630845
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Fluorodeoxyglucose F18, Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI), General Electric (GE) SIGNA PET/MR
Drug · Procedure · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 5, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT01017133
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography
Radiation · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 5, 2026, 5:47 PM EDT
Recruiting Early Phase 1 Interventional

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

NCT06453915
View directory record Official record
Conditions
Positron Emission Tomography
Interventions
18F-DPA-714, 18F-FDG
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 5, 2026, 5:47 PM EDT